Back to top
more

Aurora Cannabis (ACB)

(Delayed Data from NSDQ)

$6.25 USD

6.25
2,700,711

+0.50 (8.70%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $6.31 +0.06 (0.96%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Apyx Medical (APYX) to Report Q1 Earnings: What's in Store?

Apyx Medical (APYX) likely to gain from J-plasma technology in Q1; margins under pressure.

Can Dental Growth Drive Henry Schein's (HSIC) Q1 Earnings?

Henry Schein (HSIC) is consistently riding on segmental strength at Dental, Medical and Technology plus Value-Added Services.

Nalak Das headshot

Invest Carefully in Rosy But Risky Marijuana Industry

The much-awaited Cannabis Banking Bill was finally passed by the House Financial Services Committee on Mar 28.

Can Steady CAG Growth Drive IDEXX's (IDXX) Q1 Earnings?

Idexx (IDXX) is expected to continue reporting solid revenue growth on robust CAG performance.

Aurora Cannabis Inc. (ACB) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.06, marking a +0.22% move from the previous day.

Can Breast Health Growth Drive Hologic's (HOLX) Q2 Earnings?

Hologic's (HOLX) Breast Health segment is witnessing a rapid uptick on the back of large installed base of market-leading, clinically differentiated Genius 3D mammography systems.

Will Pharmacy Services Drive CVS Health's (CVS) Q1 Earnings?

Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.

Is a Beat in the Offing for Humana's (HUM) Q1 Earnings?

Humana's (HUM) Q1 earnings are likely to gain on higher membership and a solid Medicare Advantage.

Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?

With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.

Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?

Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.

Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?

ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.

Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis

Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis

Tracey Ryniec headshot

Should You Buy Lottery Stocks?

Like playing the lottery, some stocks lure in investors with the promise of possible riches.

Can Front Line Care Drive Hill-Rom's (HRC) Q2 Earnings?

Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.

Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.05, marking a -1.95% move from the previous day.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.

Sanghamitra Saha headshot

Likely Canopy-Acreage Deal Looks Good Enough to Boost ETF MJ

Canopy Growth will probably purchase the rights to buy Acreage Holdings to tap the growing potential of the U.S. marijuana market. This should bolster the ETF MJ.

Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know

Aurora Cannabis Inc. (ACB) closed at $8.96 in the latest trading session, marking a +0.9% move from the prior day.

The Zacks Analyst Blog Highlights: Constellation Brand, Canopy Growth, Aurora Cannabis, Cronos and Tilray

The Zacks Analyst Blog Highlights: Constellation Brand, Canopy Growth, Aurora Cannabis, Cronos and Tilray

Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.01, marking a -1.74% move from the previous day.

Daniel Laboe headshot

Constellation Makes Big Cannabis Bet

Constellation Brands have been continuously adding to their stake in Canopy Growth (CGC), which is the leading player in the Canadian cannabis market. STZ just added another $4 billion investment in August bringing its total stake in Canopy to 38% ownership.

Neena Mishra headshot

Best Performing ETFs of the First Quarter

Major indexes posted their best quarterly performance since the financial crisis; here are some ETFs that soared during the quarter

Sweta Killa headshot

Short Sellers and Easing Rules Boost Pot ETF Higher

Along with easing rules, short-selling of the stocks led to the spike in the pot ETF.

Nitish Marwah headshot

Marijuana Banking, IPOs & Weed Votes: Will Hemp Grow Higher? (Revised)

Experts are of the view that the marijuana industry would generate as much as $5 billion in annual revenues over the next two years.

Aurora Cannabis Inc. (ACB) Outpaces Stock Market Gains: What You Should Know

Aurora Cannabis Inc. (ACB) closed at $9.18 in the latest trading session, marking a +1.32% move from the prior day.